https://orcid.org/0000-0001-8467-9257
Pivotal TRANSCEND NHL 001 study demonstrated the efficacy and safety of liso-cel as third-line or later treatment for patients with R/R LBCL.
With 2-year follow-up, liso-cel showed high response rates, durable remissions, and a manageable safety profile for patients with R/R LBCL.
Abstract
Lisocabtagene maraleucel (liso-cel) demonstrated significant efficacy with a manageable safety profile as third-line or later treatment for patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) in the TRANSCEND NHL 001 study. Primary end points were adverse events (AEs), dose-limiting toxicities, and objective response rate (ORR) per independent review committee. Key secondary end points were complete response (CR) rate, duration of response (DOR), progression-free survival (PFS), and overall survival (OS). After 2-year follow-up, patients could enroll in a separate study assessing long-term (≤15 years) safety and OS. Liso-cel–treated patients (N = 270) had a median age of 63 years (range, 18-86 years) and a median of 3 prior lines (range, 1-8) of systemic therapy, and 181 of them (67%) had chemotherapy-refractory LBCL. Median follow-up was 19.9 months. In efficacy-evaluable patients (N = 257), the ORR was 73% and CR rate was 53%. The median (95% confidence interval) DOR, PFS, and OS were 23.1 (8.6 to not reached), 6.8 (3.3-12.7), and 27.3 months (16.2-45.6), respectively. Estimated 2-year DOR, PFS, and OS rates were 49.5%, 40.6%, and 50.5%, respectively. In the 90-day treatment-emergent period (N = 270), grade 3 to 4 cytokine release syndrome and neurological events occurred in 2% and 10% of patients, respectively. The most common grade ≥3 AEs in treatment-emergent and posttreatment-emergent periods, respectively, were neutropenia (60% and 7%) and anemia (37% and 6%). Liso-cel demonstrated durable remissions and a manageable safety profile with no new safety signals during the 2-year follow-up in patients with R/R LBCL. These trials were registered at www.ClinicalTrials.gov as #NCT02631044 and #NCT03435796.
References
1.
Van Den Neste
E
, Schmitz
N
, Mounier
N
, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study
. Bone Marrow Transplant
. 2016
;51
(1
):51
-57
.2.
González-Barca
E
, Boumendil
A
, Blaise
D
, et al. Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
. Bone Marrow Transplant
. 2020
;55
(2
):393
-399
.3.
Crump
M
, Neelapu
SS
, Farooq
U
, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
. Blood
. 2017
;130
(16
):1800
-1808
.4.
Thanarajasingam
G
, Maurer
MJ
, Farooq
U
, et al. Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era
. Br J Haematol
. 2018
;183
(1
):149
-152
.5.
El-Galaly
TC
, Cheah
CY
, Bendtsen
MD
, et al. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma
. Eur J Cancer
. 2018
;93
:57
-68
.6.
Pfreundschuh
M
. How I treat elderly patients with diffuse large B-cell lymphoma
. Blood
. 2010
;116
(24
):5103
-5110
.7.
Schuster
SJ
, Svoboda
J
, Chong
EA
, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas
. N Engl J Med
. 2017
;377
(26
):2545
-2554
.8.
Neelapu
SS
, Locke
FL
, Bartlett
NL
, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma
. N Engl J Med
. 2017
;377
(26
):2531
-2544
.9.
Maude
SL
, Laetsch
TW
, Buechner
J
, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
. N Engl J Med
. 2018
;378
(5
):439
-448
.10.
Abramson
JS
, Palomba
ML
, Gordon
LI
, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
. Lancet
. 2020
;396
(10254
):839
-852
.11.
Munshi
NC
, Anderson
LD
, Shah
N
, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma
. N Engl J Med
. 2021
;384
(8
):705
-716
.12.
Roex
G
, Timmers
M
, Wouters
K
, et al. Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma
. J Hematol Oncol
. 2020
;13
(1
):164
.13.
Turtle
CJ
, Hanafi
LA
, Berger
C
, et al. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells
. Sci Transl Med
. 2016
;8
(355
):355ra116
.14.
Hay
KA
, Hanafi
L-A
, Li
D
, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy
. Blood
. 2017
;130
(21
):2295
-2306
.15.
Ramsborg
CG
, Guptill
P
, Weber
C
, et al. JCAR017 is a defined composition CAR T cell product with product and process controls that deliver precise doses of CD4 and CD8 CAR T cell to patients with NHL
. Blood
. 2017
;130
(suppl 1
):4471
.16.
Riddell
SR
, Sommermeyer
D
, Berger
C
, et al. Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition
. Cancer J
. 2014
;20
(2
):141
-144
.17.
Swerdlow
SH
, Campo
E
, Pileri
SA
, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms
. Blood
. 2016
;127
(20
):2375
-2390
.18.
Hobbs
BP
, Barata
PC
, Kanjanapan
Y
, et al. Seamless designs: current practice and considerations for early-phase drug development in oncology
. J Natl Cancer Inst
. 2019
;111
(2
):118
-128
.19.
US Food and Drug Administration
. Expansion cohorts: use in first-in-human clinical trials to expedite development of oncology drugs and biologics - guidance for industry
. Accessed 9 November 2023. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expansion-cohorts-use-first-human-clinical-trials-expedite-development-oncology-drugs-and-biologics.20.
Cheson
BD
, Fisher
RI
, Barrington
SF
, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification
. J Clin Oncol
. 2014
;32
(27
):3059
-3068
.21.
Lee
DW
, Gardner
R
, Porter
DL
, et al. Current concepts in the diagnosis and management of cytokine release syndrome
. Blood
. 2014
;124
(2
):188
-195
.22.
US Department of Health and Human Services
. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.03
. Accessed 11 October 2022. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf.23.
Ogasawara
K
, Lymp
J
, Mack
T
, et al. In vivo cellular expansion of lisocabtagene maraleucel and association with efficacy and safety in relapsed/refractory large B-cell lymphoma
. Clin Pharmacol Ther
. 2022
;112
(1
):81
-89
.24.
Ogasawara
K
, Dodds
M
, Mack
T
, Lymp
J
, Dell'Aringa
J
, Smith
J
. Population cellular kinetics of lisocabtagene maraleucel, an autologous CD19-directed chimeric antigen receptor T-cell product, in patients with relapsed/refractory large B-cell lymphoma
. Clin Pharmacokinet
. 2021
;60
(12
):1621
-1633
.25.
Kamdar
M
, Solomon
SR
, Arnason
J
, et al. for the TRANSFORM Investigators. Lisocabtagene maraleucel, a CD19-directed chimeric antigen receptor T-cell therapy, versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma: results from the randomised, open-label TRANSFORM phase 3 study
. Lancet
. 2022
;399
(10343
):2294
-2308
.26.
Pedersen-Bjergaard
J
, Andersen
MK
, Christiansen
DH
. Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation
. Blood
. 2000
;95
(11
):3273
-3279
.27.
Radivoyevitch
T
, Dean
RM
, Shaw
BE
, et al. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma
. Leuk Res
. 2018
;74
:130
-136
.28.
Cordeiro
A
, Bezerra
ED
, Hirayama
AV
, et al. Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells
. Biol Blood Marrow Transplant
. 2020
;26
(1
):26
-33
.29.
Elstrom
RL
, Martin
P
, Ostrow
K
, et al. Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies
. Clin Lymphoma Myeloma Leuk
. 2010
;10
(3
):192
-196
.30.
Schuster
SJ
, Tam
CS
, Borchmann
P
, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study
. Lancet Oncol
. 2021
;22
(10
):1403
-1415
.31.
Neelapu
SS
. Managing the toxicities of car T-cell therapy
. Hematol Oncol
. 2019
;37
(suppl 1
):48
-52
.32.
Locke
FL
, Ghobadi
A
, Jacobson
CA
, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
. Lancet Oncol
. 2019
;20
(1
):31
-42
.33.
Yakoub-Agha
I
, Chabannon
C
, Bader
P
, et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
. Haematologica
. 2020
;105
(2
):297
-316
.34.
Jacobson
C
, Locke
FL
, Ghobadi
A
, et al. Long-term (≥ 4 year and ≥ 5 year) overall survival (OS) by 12-and 24-month event-free survival (EFS): an updated analysis of ZUMA-1, the pivotal study of axicabtagene ciloleucel (axi-cel) in patients (pts) with refractory large B-cell lymphoma (LBCL)
. Blood
. 2021
;138
(suppl 1
):1764
.35.
Schuster
SJ
, Bishop
MR
, Tam
CS
, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma
. N Engl J Med
. 2019
;380
(1
):45
-56
.36.
Porter
D
, Frey
N
, Wood
PA
, Weng
Y
, Grupp
SA
. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
. J Hematol Oncol
. 2018
;11
(1
):35
.37.
Maloney
DG
, Kuruvilla
J
, Liu
FF
, et al. Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma
. J Hematol Oncol
. 2021
;14
(1
):140
.38.
Cartron
G
, Fox
CP
, Liu
FF
, et al. Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel
. Exp Hematol Oncol
. 2022
;11
(1
):17
.39.
Van Le
H
, Van Naarden Braun
K
, Nowakowski
GS
, et al. Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma
. Leuk Lymphoma
. 2023
;64
(3
):573
-585
.© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
2024
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal